Research programme: bladder cancer therapeutic - DexTech Medical AB

Drug Profile

Research programme: bladder cancer therapeutic - DexTech Medical AB

Alternative Names: CatDex

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DexTech Medical
  • Class Drug conjugates; Glucans
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bladder cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bladder-cancer in Sweden (Intravesicular)
  • 12 Jun 2012 Preclinical trials in Bladder cancer in Sweden (Intravesicular)
  • 12 Dec 2004 Early research in Bladder cancer in Sweden (Intravesicular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top